29 selected records with a cited source date in 2010. This archive is selective and does not imply continuous monitoring or complete historical coverage.
PeptideScanner retained ClinicalTrials.gov record NCT00840671 at 2026-11-16T17:33:14.861Z. Its registry update date was 2010-12-28, and PeptideScanner's reviewed identity mapping was cerebrolysin.
PeptideScanner retained ClinicalTrials.gov record NCT00268892 at 2026-11-15T21:52:09.579Z. Its registry update date was 2010-12-24, and PeptideScanner's reviewed identity mapping was degarelix.
The Federal Register published notice 2010-31583, attributed to FDA and its parent HHS department, on 2010-12-16. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; ANGIOMAX,” and PeptideScanner's exact reviewed identity mapping connects the document to Bivalirudin.
PeptideScanner retained ClinicalTrials.gov record NCT00116753 at 2026-11-15T21:52:09.579Z. Its registry update date was 2010-12-10, and PeptideScanner's reviewed identity mapping was degarelix.
PubMed lists PMID 17461696 in Pharmacotherapy as Comment, Journal Article, Review, with publication-date metadata of 2007-05 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained PubMed bibliographic metadata for PMID 11569188 at 2026-07-30T22:26:16.761Z. PubMed recorded a metadata revision date of 2010-11-18 and an Entrez history date of 2001-09-25. PeptideScanner associated this retained record with the identity slug semax. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 15817669 at 2026-07-30T22:26:16.765Z. PubMed recorded a metadata revision date of 2010-11-18 and an Entrez history date of 2005-04-09. PeptideScanner associated this retained record with the identity slug cjc-1295. These dates describe PubMed metadata history, not the article's original publication date.
The official Drugs@FDA dataset lists original submission 1 for BLA 022505 with status AP dated 2010-11-10, and names tesamorelin acetate among the application record's active ingredients.
PeptideScanner retained ClinicalTrials.gov record NCT00002881 at 2026-07-30T22:25:23.114Z. Its registry update date was 2010-11-09, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT00746031 at 2026-11-15T22:02:39.332Z. Its registry update date was 2010-10-25, and PeptideScanner's reviewed identity mapping was cetrorelix.
PeptideScanner retained ClinicalTrials.gov record NCT01208649 at 2026-07-30T22:25:23.111Z. Its registry update date was 2010-09-24, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained PubMed bibliographic metadata for PMID 20861602 at 2026-07-30T22:26:16.803Z. PubMed recorded a metadata revision date of 2010-09-23 and an Entrez history date of 2010-09-24. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained ClinicalTrials.gov record NCT00460382 at 2026-11-16T01:41:15.051Z. Its registry update date was 2010-09-17, and PeptideScanner's reviewed identity mapping was enfuvirtide.
PeptideScanner retained ClinicalTrials.gov record NCT00259298 at 2026-07-30T22:25:23.113Z. Its registry update date was 2010-08-11, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT01178996 at 2026-11-15T22:10:40.222Z. Its registry update date was 2010-08-10, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.
PubMed lists PMID 20530970 in Journal of molecular microbiology and biotechnology as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2010-06-08 (day precision). PeptideScanner associated the retained record with the identity slug peg-mgf. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT01134848 at 2026-11-16T01:34:15.953Z. Its registry update date was 2010-06-02, and PeptideScanner's reviewed identity mapping was secretin.
PeptideScanner retained ClinicalTrials.gov record NCT00638976 at 2026-11-15T21:59:29.646Z. Its registry update date was 2010-05-28, and PeptideScanner's reviewed identity mapping was eptifibatide.
PeptideScanner retained ClinicalTrials.gov record NCT00439829 at 2026-11-15T22:02:39.332Z. Its registry update date was 2010-05-25, and PeptideScanner's reviewed identity mapping was cetrorelix.
The Federal Register published notice 2010-11038, attributed to FDA and its parent HHS department, on 2010-05-11. Its official title is “Pediatric Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin.
PeptideScanner retained ClinicalTrials.gov record NCT00005906 at 2026-07-30T22:25:23.111Z. Its registry update date was 2010-04-30, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT00832091 at 2026-11-16T01:44:56.605Z. Its registry update date was 2010-03-30, and PeptideScanner's reviewed identity mapping was thymosin-beta-4.
The Federal Register published notice 2010-6169, attributed to FDA and its parent HHS department, on 2010-03-22. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Tesamorelin.
PeptideScanner retained ClinicalTrials.gov record NCT00262054 at 2026-11-15T21:58:19.888Z. Its registry update date was 2010-03-15, and PeptideScanner's reviewed identity mapping was bivalirudin.
The official Drugs@FDA dataset lists original submission 1 for NDA 022437 with status AP dated 2010-03-10, and names triptorelin pamoate among the application record's active ingredients.
The Federal Register published notice 2010-4159, attributed to FDA and its parent HHS department, on 2010-03-01. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; FIRMAGON,” and PeptideScanner's exact reviewed identity mapping connects the document to Degarelix.
PeptideScanner retained ClinicalTrials.gov record NCT00382174 at 2026-11-16T01:44:56.605Z. Its registry update date was 2010-02-01, and PeptideScanner's reviewed identity mapping was thymosin-beta-4.
The official Drugs@FDA dataset lists original submission 1 for NDA 022341 with status AP dated 2010-01-25, and names liraglutide among the application record's active ingredients.
The Federal Register published notice 2010-785, attributed to FDA and its parent HHS department, on 2010-01-19. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Tesamorelin.